Alexandra Balcom Nuvalent, Inc. (NUVL) insider trading activity

Alexandra Balcom is Chief Financial Officer of Nuvalent, Inc.. Currently has a direct ownership of 99,233 shares of NUVL, which is worth approximately $9.58 Million. The most recent transaction as insider was on Jan 07, 2026, when has been sold 17,500 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 99.2K

60.74% 3M change

60.74% 12M change

Total Value Held $9.58 Million

Alexandra Balcom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2026	BUY Grant, award, or other acquisition	-	17,500 Added 14.99%	99,233 Class A Common Stock
Jan 06 2026	SELL Open market or private sale	$310,115 $97.49 p/Share	3,181 Reduced 3.75%	81,733 Class A Common Stock
Jan 05 2026	SELL Open market or private sale	$412,374 $97.35 p/Share	4,236 Reduced 4.75%	84,914 Class A Common Stock
Dec 22 2025	BUY Exercise of conversion of derivative security	$37,260 $1.08 p/Share	34,500 Added 27.9%	89,150 Class A Common Stock
Dec 08 2025	SELL Open market or private sale	$784,978 $110.81 p/Share	7,084 Reduced 11.48%	54,650 Class A Common Stock
Nov 18 2025	SELL Open market or private sale	$75,874 $104.08 p/Share	729 Reduced 1.17%	61,734 Class A Common Stock
Nov 18 2025	BUY Exercise of conversion of derivative security	$52,743 $72.35 p/Share	729 Added 1.15%	62,463 Class A Common Stock

Nov 17 2025	SELL Open market or private sale	$1,995,200 $99.76 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Nov 17 2025	BUY Exercise of conversion of derivative security	$792,400 $39.62 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Oct 15 2025	SELL Open market or private sale	$144,014 $85.57 p/Share	1,683 Reduced 2.65%	61,734 Class A Common Stock
Oct 15 2025	BUY Exercise of conversion of derivative security	$31,859 $18.93 p/Share	1,683 Added 2.59%	63,417 Class A Common Stock
Oct 14 2025	SELL Open market or private sale	$1,744,800 $87.24 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 14 2025	BUY Exercise of conversion of derivative security	$378,600 $18.93 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Oct 13 2025	SELL Open market or private sale	$1,772,400 $88.62 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 13 2025	BUY Exercise of conversion of derivative security	$258,200 $12.91 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Oct 01 2025	SELL Open market or private sale	$1,718,000 $85.9 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Oct 01 2025	BUY Exercise of conversion of derivative security	$258,200 $12.91 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Sep 30 2025	SELL Open market or private sale	$1,701,200 $85.06 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Sep 30 2025	BUY Exercise of conversion of derivative security	$137,800 $6.89 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Sep 29 2025	SELL Open market or private sale	$645,055 $85.01 p/Share	7,588 Reduced 10.95%	61,734 Class A Common Stock
Sep 29 2025	BUY Exercise of conversion of derivative security	$52,281 $6.89 p/Share	7,588 Added 9.87%	69,322 Class A Common Stock
Jul 16 2025	SELL Open market or private sale	$1,250,970 $85.1 p/Share	14,700 Reduced 19.23%	61,734 Class A Common Stock
Jul 16 2025	BUY Exercise of conversion of derivative security	$278,271 $18.93 p/Share	14,700 Added 16.13%	76,434 Class A Common Stock
Jul 15 2025	SELL Open market or private sale	$446,419 $84.23 p/Share	5,300 Reduced 7.91%	61,734 Class A Common Stock
Jul 15 2025	BUY Exercise of conversion of derivative security	$100,329 $18.93 p/Share	5,300 Added 7.33%	67,034 Class A Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

Director